PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

Résumé détaillé

Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwide Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal…

Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwide

Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission

Conference call and webcast to be held today, November 13, at 8:30 AM EST

NEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the third quarter ended September 30, 2026.

The webcast will take place on Friday, November 13, 2026, at 8:30 AM EST and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.

"We're very encouraged by developments across the PAVmed portfolio," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid's largest common shareholder, PAVmed stands to benefit directly from Lucid's substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris.

1 Included in general and administrative expenses in the financial statements.

3…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.